Viewing Study NCT03422393

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:14 AM
Ignite Modification Date: 2026-02-21 @ 8:07 AM
Study NCT ID: NCT03422393
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-07-05
First Post: 2018-01-30
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
Sponsor: Michael Choi
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
None Small Lymphocytic Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None venetoclax View
None ibrutinib View
None high-dose ibrutinib View
None chronic lymphocytic leukemia View
None progressive disease View
None Small Lymphocytic Lymphoma View
None cancer View